Public funding of large-scale clinical trials in Australia

Medical Journal of Australia

Volumn 179, Issue 10, 2003, Pages 519-520

  McNeil, John J ^a   Nelson, Mark R ^a   Tonkin, Andrew M ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIURETIC AGENT; SEX HORMONE;

AUSTRALIA; BUDGET; CHRONIC DISEASE; CLINICAL TRIAL; DRUG COST; EDITORIAL; FINANCIAL MANAGEMENT; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MENOPAUSE RELATED DISORDER; OUTCOMES RESEARCH; PUBLIC HEALTH; RISK BENEFIT ANALYSIS;

EID: 0345375414     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2003.tb05674.x     Document Type: Editorial

References (10)

1. Reid CM, Wing LM, Graham DH. A new paradigm for funding cardiovascular-outcome research in general practice. The Second Australian National Blood Pressure Study. Med J Aust 1998; 169: 349-350.
2. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ 2003; 326: 1167-1170.
3. Australian Department of Health and Ageing. Pharmaceutical Benefits Scheme Table 10(a): Significant drug groups by highest government costs. Available at: www.health.gov.au/pbs/general/pubs/pbbexp/pbjun03/pdf/book23.pdf (accessed Sep 2003).
4. Nelson MR, McNeil JJ, Peeters A, et al. PBS/RPBS cost implications of trends and guideline recommendations in the pharmacological management of hypertension in Australia, 1994-1998. Med J Aust 2001; 174: 565-568.
5. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
6. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-333.
8. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 update. Circulation 2002; 106: 388-391.
9. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials [comment]. JAMA 1998; 280: 1930-1935.
10. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: Review of epidemiologic studies. J Clin Epidemiol 2002; 55: 157-163.